Wednesday, July 8, 2026

pharma · Advanced solid tumors · Advanced Solid Tumors · TTRX

Turn Therapeutics

Turn Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Westlake Village, USA HQ
2015 Founded
11 Employees
Public company Type
TTRX · NYSE Ticker
Company details
Status
Public
HQ
Westlake Village, USA
Founded
2015
Employees
11
Programs
6
Drugs
3
Patents
40
Intelligence · Clinical Programs

Turn Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Turn Therapeutics.

Turn Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. GX-03

    Turn Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial
  2. GX-03

    Turn Therapeutics

    Eczema Atopic Dermatitis

    phase 2 other active

    1 trial
  3. Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  4. TPX-0005-07

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Turn Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.